Tributary Capital Management LLC lifted its position in shares of Balchem Co. (NASDAQ:BCPC - Free Report) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,255 shares of the basic materials company's stock after purchasing an additional 1,634 shares during the period. Balchem comprises 1.7% of Tributary Capital Management LLC's portfolio, making the stock its 22nd largest position. Tributary Capital Management LLC owned 0.42% of Balchem worth $22,209,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Watts Gwilliam & Co. LLC lifted its holdings in Balchem by 63.7% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company's stock worth $5,438,000 after acquiring an additional 13,642 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Balchem by 1.7% in the third quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company's stock worth $80,782,000 after purchasing an additional 7,721 shares in the last quarter. Stifel Financial Corp increased its holdings in shares of Balchem by 26.2% during the third quarter. Stifel Financial Corp now owns 11,893 shares of the basic materials company's stock valued at $2,093,000 after purchasing an additional 2,467 shares during the period. Geode Capital Management LLC increased its holdings in shares of Balchem by 3.1% during the third quarter. Geode Capital Management LLC now owns 928,904 shares of the basic materials company's stock valued at $163,514,000 after purchasing an additional 27,979 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Balchem by 2.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 361,970 shares of the basic materials company's stock valued at $63,707,000 after purchasing an additional 7,562 shares in the last quarter. 87.91% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
BCPC has been the topic of a number of recent analyst reports. HC Wainwright boosted their price target on shares of Balchem from $185.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. StockNews.com raised Balchem from a "hold" rating to a "buy" rating in a research note on Monday, October 28th.
View Our Latest Research Report on Balchem
Balchem Price Performance
Balchem stock traded down $1.98 during midday trading on Friday, hitting $160.23. The company's stock had a trading volume of 96,824 shares, compared to its average volume of 98,411. Balchem Co. has a 12 month low of $137.69 and a 12 month high of $186.03. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $5.21 billion, a PE ratio of 43.07, a price-to-earnings-growth ratio of 4.36 and a beta of 0.69. The stock's 50-day moving average price is $168.92 and its 200-day moving average price is $170.88.
Balchem Increases Dividend
The business also recently declared an annual dividend, which was paid on Friday, January 17th. Investors of record on Thursday, December 26th were given a $0.87 dividend. This is a positive change from Balchem's previous annual dividend of $0.79. The ex-dividend date was Thursday, December 26th. This represents a dividend yield of 0.4%. Balchem's dividend payout ratio (DPR) is 23.39%.
Balchem Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.